Endo International (ENDP) was slipping past 11% after saying its treatment candidate for a condition called "frozen" shoulder didn't show statistical significance over placebo in terms of efficacy in improving shoulder function, based on data from its phase 2 trial.
Celldex Therapeutics (CLDX) said its candidate therapy for moderate to severe chronic spontaneous urticaria (CSU), barzolvolimab, showed positive results in an ongoing phase 1b clinical trial. Celldex Therapeutics was recently down more than 8%.
Cytokinetics (CYTK) was up more than 7% after saying it has priced a private placement of $450 million principal amount of 3.5% convertible senior notes due 2027.
|-- Earnings Flash (STLC.TO) STELCO HOLDINGS Reports ...|
|-- Earnings Flash (STLC.TO) STELCO HOLDINGS Posts Ad...|
|-- Earnings Flash (CWV.V) CROWN POINT ENERGY Reports...|
|-- Earnings Flash (IDG.TO) INDIGO BOOKS & MUSIC Repo...|
|Blue Bird Swings to Q3 Loss; Cuts FY22 Sales Outlook|